Last quarter (Q ), Virax Biolabs Group Ltd. Class A's total revenue was $―, a decrease of ― from the same quarter last year. In Q, Virax Biolabs Group Ltd. Class A's net income was $―. See Virax Biolabs Group Ltd. Class A’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Mar 20
Total Revenue	-	$ 8.56K	-	$ 123.82K	$ 99.88K
Cost of Revenue	-	$ 9.93K	-	$ 133.25K	$ 54.13K
Gross Profit	-	$ -1.36K	-	$ -9.43K	$ 45.75K
Operating Expense	-	$ 5.73M	$ 1.73M	$ 635.10K	$ 696.99K
Operating Income	-	$ -5.73M	$ -1.73M	$ -644.54K	$ -651.24K
Net Non Operating Interest Income Expense	-	-	-	$ -28.64K	$ -90.69K
Other Income Expense	-	$ 5.17M	$ 3.38M	$ 266.00	$ 2.47K
Pretax Income	-	$ -16.37M	$ -5.21M	$ -672.91K	$ -739.46K
Tax Provision	-	-	-	$ 0.00	$ 0.00
Earnings From Equity Interest Net Of Tax	-	$ -111.00	-	-	-
Net Income Common Stockholders	-	$ -16.37M	$ -5.25M	$ -650.98K	$ -710.44K
Basic EPS	-	$ -0.51	$ -0.18	$ -0.06	$ -0.06
Diluted EPS	-	$ -0.51	$ -0.18	$ -0.06	$ -0.06
Basic Average Shares	-	$ 10.63M	$ 9.56M	$ 11.37M	$ 11.37M
Diluted Average Shares	-	$ 10.63M	$ 9.56M	$ 11.37M	$ 11.37M
Dividend Per Share	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-
Total Expenses	-	$ 5.74M	$ 1.73M	$ 768.36K	$ 751.12K
Net Income From Continuing And Discontinued Operation	-	$ -16.37M	$ -5.25M	$ -650.98K	$ -710.44K
Normalized Income	-	-	-	$ -650.98K	$ -710.44K
Interest Expense	-	-	-	$ 28.64K	$ 90.69K
EBIT	-	$ -16.36M	$ -5.19M	$ -644.27K	$ -648.77K
EBITDA	-	$ -16.36M	$ -5.19M	$ -644.27K	$ -648.77K

Currency in USD

Virax Biolabs Group Ltd. Class A Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing